A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of HS-10384 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)
Latest Information Update: 06 May 2024
At a glance
- Drugs HS 10384 (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 06 May 2024 New trial record